For decades, scientists have focused on amyloid plaques—abnormal clumps of misfolded proteins that accumulate between neurons ...

Patients' own stem cells to replace damaged dopamine cells in Parkinson’s disease, offering new hope. Parkinson's disease - ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

The face's expressions can change with Parkinson's disease, and facial masking (also called masked facies, or hypomimia) occurs in roughly half to 70% of all people diagnosed with the ...

This cover highlights the article Multimodal mechanisms of human centriole engagement and disengagement by Kei K. Ito, Shoji Hata, Daiju Kitagawa and colleagues. The cover image depicts the centriole ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Biotech startup Cellino, cofounded in 2017 by CEO and Forbes 30 Under 30 alumna Nabiha Saklayen, is now one step closer to scaling iPSC manufacturing ... for people with Parkinson’s disease ...

There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain stimulator that could benefit patients with the motor condition.

--(BUSINESS WIRE)--#biomanufacturing--Cellino today announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous ...